REITHERA EXPANDS LARGE-SCALE VIRAL VECTOR PRODUCTION CAPABILITIES WITH OPENING OF NEW MANUFACTURING FACILITY Read more
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline Read more
FDA Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients Read more
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome Read more